BPC-157: Mechanisms, Research Applications, and Purity Standards
BPC-157 is one of the most studied peptides in preclinical research. A look at what the animal model literature examines, why purity standards decide whether results replicate, and how Peptagon documents each lot.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a stable 15 amino acid fragment of a protective protein identified in gastric juice. It is one of the most widely studied peptides in preclinical research, with published work examining its activity in models of connective tissue injury, gastrointestinal mucosal damage and vascular signaling.
What the preclinical literature examines
In rodent models, researchers have reported accelerated recovery of muscle, tendon and ligament tissue, alongside observations of growth factor receptor upregulation in fibroblasts. A separate body of work examines gastroprotective activity, including mucosal protection in chemically induced injury models. These findings describe laboratory observations in animal and cell models. They are not evidence of effects in humans, and BPC-157 is not approved for human or veterinary use.
Why purity standards matter in BPC-157 research
Peptide synthesis can leave behind truncated sequences, residual solvents and oxidation byproducts. In a research setting those impurities confound results and make replication difficult. Every published Peptagon BPC-157 lot is independently tested by a US laboratory across five checks: HPLC purity, identity confirmation, measured quantity, endotoxin (LAL) and sterility (PCR). Current published lots verify at 99.0% purity or higher, and the lot specific certificate of analysis is linked from the product page.
Research formats
BPC-157 is cataloged as a lyophilized powder (vial), a pre-measured solution and an oral tablet research format, so laboratories can match the format to their documentation and handling workflows.
All Peptagon products are for laboratory research use only. Not for human or veterinary use.
